Mumbai: The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Financial Highlights:
|
Particulars |
Q3 FY25 |
Q3 FY24 |
|
Revenues (in Rs Cr) |
185.65 |
140.07 |
|
Gross Profit (in Rs Cr) |
123.87 |
85.45 |
|
EBITDA (in Rs Cr) |
65.95 |
41.49 |
|
EBITDA Margin |
35.50% |
29.60% |
|
PAT (in Rs Cr) |
46.78 |
29.78 |
|
PAT Margin |
25.2% |
21.30% |
|
Quarterly EPS (in Rs) |
5.82 |
3.70 |
Key Highlights for Q3 FY25:
In the third quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs. 185.65 crore compared to Rs. 140.07 crore in Q3 FY24.
Gross Profit for Q3 FY25 stood at Rs. 123.87 crore, with a growth of 45% compared to Rs. 85.45 crore in Q3 FY24.
EBITDA for Q3 FY25 stood at Rs. 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs. 41.49 crore in Q3 FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY.
The Profit After Tax (PAT) increased by 57% for Q3 FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3 FY24.
The PAT Margin stood at 25.2% in Q3 FY25, compared to 21.30% in Q3 FY24.
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, Our Q3FY25 results underscore Supriya Lifescience`s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth.”